Aardvark Therapeutics, Inc.
AARD· Nasdaq
AARDAardvark Therapeutics, Inc.
Filed Aug 11, 2026 · 10-Q · 42 days after period end · 0001193125-26-344987
| Metric | Q2 2026 | Q2 2025 | Q2 2024 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | — |
| Net Income | -$14.39M | -$14.37M | -$5.45M |
| EPS Diluted | -$0.66 | -$0.66 | -$1.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aardvark Therapeutics, Inc. · CIK 1774857 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end
